Compared with usual care, a system of electronic provider notification more often enabled patients diagnosed with severe ...

Label updates include simplified twice-yearly echo monitoring for eligible CAMZYOS patients in the maintenance phase and expanded patient eligibility with reduced contraindication ...

Princeton: Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has updated the U.S.

Whereas obesity is a common confounder when interpreting natriuretic peptide values, and the presence of atrial fibrillation has an important influence on pretest probability, other confounders are ...

A rare case of cor triatriatum was diagnosed in a 34-year-old woman using transoesophageal echocardiography after initial ...

The findings from this single-center retrospective study compare outcomes between 2 groups of patients living with connective ...

CAMZYOS reduces left ventricular ejection fraction (LVEF) and can cause heart failure due to systolic dysfunction. Echocardiogram assessments of LVEF are required prior to and during treatment ...

Camzyos is an oral, selective allosteric and reversible inhibitor of cardiac myosin. It was approved in April 2022 for the treatment of adults with symptomatic New York Heart Association (NYHA) class ...

In addition, demographic, comorbidity, echocardiography and medication data was obtained and a cox-regression analysis was performed to identify predictors of AF after HF hospitalisation. The authors ...

President Donald J. Trump underwent his annual physical examination at Walter Reed National Military Medical Center, as ...

A young man’s undiagnosed acromegaly leads to severe cardiac complications, highlighting the genetic links and diagnostic ...